Leerink Partnrs Raises Earnings Estimates for Medtronic

Medtronic PLC (NYSE:MDT) – Leerink Partnrs upped their FY2026 earnings estimates for Medtronic in a research report issued to clients and investors on Tuesday, November 18th. Leerink Partnrs analyst M. Kratky now expects that the medical technology company will post earnings of $5.64 per share for the year, up from their prior estimate of $5.63. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. Leerink Partnrs also issued estimates for Medtronic’s FY2028 earnings at $6.63 EPS and FY2029 earnings at $7.14 EPS.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS.

Several other equities analysts have also commented on the stock. Argus raised their target price on shares of Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a report on Tuesday, August 26th. Morgan Stanley lifted their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price target on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Finally, The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and an average price target of $109.72.

Medtronic Stock Down 1.0%

MDT stock opened at $99.36 on Friday. Medtronic has a 52 week low of $79.29 and a 52 week high of $102.59. The business has a 50-day simple moving average of $94.90 and a 200 day simple moving average of $90.76. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The company has a market cap of $127.45 billion, a PE ratio of 27.37, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.

Insider Activity

In other news, Director William R. Jellison bought 2,500 shares of the company’s stock in a transaction on Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the transaction, the director owned 5,000 shares of the company’s stock, valued at $461,850. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Oarsman Capital Inc. grew its position in shares of Medtronic by 2.2% in the 3rd quarter. Oarsman Capital Inc. now owns 33,537 shares of the medical technology company’s stock valued at $3,194,000 after buying an additional 711 shares during the last quarter. WBI Investments LLC boosted its holdings in Medtronic by 17.0% in the third quarter. WBI Investments LLC now owns 3,358 shares of the medical technology company’s stock valued at $320,000 after acquiring an additional 489 shares during the last quarter. Centaurus Financial Inc. increased its position in Medtronic by 67.3% during the 3rd quarter. Centaurus Financial Inc. now owns 10,637 shares of the medical technology company’s stock valued at $1,013,000 after purchasing an additional 4,280 shares during the period. First Affirmative Financial Network raised its holdings in Medtronic by 8.0% during the 3rd quarter. First Affirmative Financial Network now owns 4,944 shares of the medical technology company’s stock worth $471,000 after purchasing an additional 365 shares during the last quarter. Finally, Caerus Investment Advisors LLC acquired a new position in shares of Medtronic in the 3rd quarter worth approximately $636,000. 82.06% of the stock is owned by institutional investors.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.